Technical hurdles associated with the manufacture of CDP323 may be encountered.

Other unexpected other unexpected obstacles are encountered.. UCB and Biogen Idec Safe HarborThis press release contains forward-looking statements regarding the development of CDP323 Drug development is with a high degree of risk of only a small number of research and development programs result in commercialization of a product factors which do so. The actual results differ materially from UCB and Biogen Idec ‘s current expectations include the risk that the company not be able to the safety and efficacy the safety and efficacy of CDP323 at each stage of the clinical trial; technical hurdles associated with the manufacture of CDP323 may be encountered; applicable legal standards can not be met or regulatory authorities may not approve CDP323;.

Could offer said Professor Chris Polman, Professor of Neurology, VU Medical Centre, Amsterdam, the Netherlands, lead investigator for the study.. The trial will compare the efficacy and safety of two doses of CDP323 monotherapy with placebo over a period of six months. This is the first time that patients with MS is suspended CDP323. Approximately 50 medical centers in Europe and in the U.S. Is expected to participate in this study. The results of this Phase II study are expected in late 2008. ‘Multiple sclerosis affects more than one million people worldwide and so far, no oral treatment has been available to An oral therapy would represent a significant advancement for patients, as they are with a new, non-invasive option of drug delivery.FDA-approved Open world first full – Dedicated Focused Ultrasound equipment.

From October the center is also FDA-approved MRgFUS is known treatments for women with small, benign tumor as fibroids. For some women offer is extended than focused ultrasonic treatments develops on other conditions of and receives FDA approval. – The opening this institution an exciting development, says James M. Chairman UVA Department of for Radiation Oncology and manager the new Centre. Our system has the first fully motivated magnets are ie there be research research and MRgFUS care. Full-time access to the devices, the pace of research and spot UVA at the tip of these the emerging field to accelerate health. .

Other Posts From "sexology":

Related Posts